The hepatitis B infection treatment market size attained a value of about USD 4.5 billion in 2023, driven by the rising cases of hepatitis infections and better diagnostic procedures. The market is further expected to grow at a CAGR of 3.6% during the forecast period of 2024-2032 to reach a value of nearly USD 6.1 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hepatitis B infection is a serious hepatic disorder caused by the Hepatitis B Virus (HBV). Hepatitis B infection is of two types, acute and chronic. The acute hepatitis B infection lasts for less than six months, while the chronic one lasts for more than six months to years.
The symptoms of hepatitis B infection depend on the age, sex, and clinical profile of the patient. The symptoms may vary from moderate to severe and include abdominal pain, joint pain, nausea and vomiting, dark urine, high fever, pale skin, weakness, and fatigue.
The main cause of the hepatitis B infection is the hepatitis B virus, which can be transmitted into the healthy body through sneezing, sexual contact, sharing of needles or any other products with the infected person. The virus can also be transmitted from infected pregnant women to their neonates.
Hepatitis B infection is diagnosed with the help of blood tests, liver ultrasound, and liver biopsy. Blood tests help in the detection of the infection and confirm whether it is acute or chronic. Ultrasound and liver biopsy help to analyse the liver damage.
The treatment of hepatitis B infection includes antiviral medications, interferon injection, and liver transplant. These medications help in the slower progression of the hepatitis B infection and thus prevent further damage to the hepatic system. Newborns and children under the age of 5 are at a higher risk of chronic hepatitis B infection.
According to this study, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Indication Type
Market Breakup by Treatment Type
Market Breakup by Diagnosis Type
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The hepatitis B infection treatment market is primarily driven by the rising cases of hepatitis B infection in developed and developing nations. According to the World Health Organisation, in 2015, around 257 patients are infected with hepatitis B infection globally. The disease burden is expected to increase in the upcoming years, which has led to increased demands for therapeutics, thus attributing to the market growth.
The hepatitis B infection treatment market is further driven by raising awareness about the disease, its pathogenesis, awareness, and treatment. Several initiatives are implemented by the government and non-government organisations to raise awareness about the transmission and preventative measures of the disease. This is anticipated to augment the market growth during the forecast period.
With the increasing patient pool, major pharmaceutical companies are working on the invention of novel and more effective therapeutic methods that are expected to bolster the hepatitis B infection treatment market development.
Other factors such as technological advancements, increased investments, better screening procedures, and novel product launches and approvals are expected to drive the hepatitis B infection treatment market growth forward in the coming years.
North America is anticipated to hold a significant share of the hepatitis B infection treatment market owing to the presence of strategic key players, advanced healthcare infrastructure, and increased adoption of improved palliative care.
The Asia Pacific region is expected to witness the fastest market growth during the forecasted period due to the rapidly developing medical diagnostic sector, favouring government initiatives, and increasing disposable incomes and economies.
The treatment of hepatitis B infection is based on the symptoms and severity of the disease. In the case of acute conditions, there is no need for any proper management technique, while in the case of chronic hepatitis, the healthcare provider prescribes several medications and treatment procedures to manage the further progression of the disease.
The standard line treatment for hepatitis B is the administration of antiviral medications, that act against the virus and thus slow down liver damage. The most used antiviral drugs are Tenofovir, Telbivudine, Entecavir, Adefovir, and Lamivudine.
Artificial or man-made versions of natural substances produced by the body are also used for the treatment of hepatitis B. These include interferon alpha-2b for providing long-term disease treatment. These drugs also aid in the prevention of cirrhosis, reduce the risk of liver cancer, and increase long-term survival.
Surgical interventions are being implemented in case of medication intolerant patients or medication failure. A liver transplant is a surgical therapeutic intervention used to eliminate the damaged liver and replaced it with a healthy one.
Other than the available treatment options, secondary care is aimed at ensuring comfort, maintaining a balanced nutritional portfolio, and improving the quality of living.
The treatment for hepatitis B is primarily aimed at providing a functional cure. This refers to the reduction in the disease markers and virus responsible for causing the disease. The currently available therapeutic strategies do suppress the viral DNA levels but fail to provide a functional cure. This brings in the need for the development of novel medicines that act against the several cycles of the chronic hepatitis B virus.
At present, there are more than thirty new HIV medications that are under clinical development and trials. The discovery of novel therapeutic agents has grabbed the attention of investors and is anticipated to stimulate the hepatitis B infection treatment market during the forecast period.
In 2021, Assembly Biosciences and Antios Therapeutics clinically collaborated for the discovery of combination therapy using the three different drug categories. The trial is evaluating the tenofovir disproxil fumarate, ATI 2173, and AB-279 in patients suffering from chronic hepatitis B infections.
Assembly, a key market player, has teamed up with Arbutus Biopharma for testing a dual combination therapy of AB-729 with Verbicorvir. The monotherapeutic trial is also being conducted by the former for investigating ABI-H3733, a core inhibitor in the treatment of hepatitis B infection.
VBI Vaccines and Bril Biosciences are conducting Phase II clinical trials for the new recombinant protein-based immunotherapeutic drug candidate for chronic hepatitis B infection. The drug has shown some promising effects in trials and has induced both T-cell and B-cell responses.
Arbutus Biopharma Corporation is also conducting Phase II trials for the novel investigational therapy, AB-729. The drug is under clinical studies for assessing its efficacy, tolerability, and adverse effects, alone and in combination.
The discovery of these novel therapeutic interventions will assist in the proper diagnosis and treatment of hepatitis B infection. The novel product launches will facilitate the expansion of the market.
The report gives an in-depth analysis of the key players involved in the hepatitis B infection treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Indication Type||
|Breakup by Treatment Type||
|Breakup by Diagnosis Type||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Hepatitis B Infection Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
18.104.22.168 Patent Status and Expiry
22.214.171.124 Timelines from Drug Development to Commercial Launch
126.96.36.199 New Drug Application
188.8.131.52.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
184.108.40.206 US FDA
220.127.116.11 EU EMA
18.104.22.168 INDIA CDSCO
22.214.171.124 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Hepatitis B Infection Treatment Market
8.1 Global Hepatitis B Infection Treatment Market Overview
8.2 Global Hepatitis B Infection Treatment Market Analysis
8.2.1 Market Overview
126.96.36.199 Global Hepatitis B Infection Treatment Market Historical Value (2017-2023)
188.8.131.52 Global Hepatitis B Infection Treatment Market Forecast Value (2024-2032)
8.2.2 Global Hepatitis B Infection Treatment Market by Indication Type
184.108.40.206 Market Overview
8.2.3 Global Hepatitis B Infection Treatment Market by Treatment Type
220.127.116.11 Market Overview
18.104.22.168.1 Antiviral Drugs
22.214.171.124.1.1 Tenofovir Disoproxil
126.96.36.199.3 Immune Modulator Drugs
188.8.131.52.3.1 Pegylated Interferon
184.108.40.206.3.2 Interferon Alpha
8.2.4 Global Hepatitis B Infection Treatment Market by Diagnosis Type
220.127.116.11 Market Overview
18.104.22.168.1 Hepatitis B Enzyme Immuno-Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests
22.214.171.124.2 Hepatitis B Nucleic Acid Amplification Tests (NAATs)
126.96.36.199.3 Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs
8.2.5 Global Hepatitis B Infection Treatment Market by Distribution Channel
188.8.131.52 Market Overview
184.108.40.206.1 Hospital Pharmacies
220.127.116.11.2 Retail Pharmacies
18.104.22.168.3 Online Pharmacies
8.2.6 Global Hepatitis B Infection Treatment Market by Region
22.214.171.124 Market Overview
126.96.36.199.1 North America
188.8.131.52.3 Asia Pacific
184.108.40.206.4 Middle East and Africa
220.127.116.11.5 Latin America
9 North America Hepatitis B Infection Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Hepatitis B Infection Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
11 Asia Pacific Hepatitis B Infection Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
12 Latin America Hepatitis B Infection Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
13 Middle East and Africa Hepatitis B Infection Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
14 Global Hepatitis B Infection Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Accord Healthcare (Intas Pharmaceuticals Ltd.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Apotex Inc. (SK Capital Partners)
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Arbutus Biopharma
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Arrowhead Pharmaceuticals, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Aurobindo Pharma
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Bristol-Myers Squibb Company
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Gilead Sciences, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 GSK plc
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Merck & Co., Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Par Pharmaceutical (Endo International plc)
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.12 Teva Pharmaceutical Industries Ltd.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.13 Zydus Healthcare Limited
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
16 Global Hepatitis B Infection Treatment Market- Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customizable as per client requirements.
The market for hepatitis B infection treatment attained a value of USD 4.5 billion in 2023.
The market is anticipated to grow at a CAGR of 3.6% during the forecast period of 2024-2032 to reach a value of USD 6.1 billion by 2032.
The market is primarily driven by the rising cases of hepatitis infections, technological advancements, increased investments, and better diagnostic procedures.
Based on the indication type, the market is categorised into acute and chronic.
Based on the treatment type, the market is segmented into antiviral drugs, vaccines, immune modulator drugs, and surgery, among others.
Based on the diagnosis type, the market is bifurcated into hepatitis B Enzyme Immuno Assay/ Enzyme-Linked Immunosorbent Assay (EIA/ELISA) tests, hepatitis B Nucleic Acid Amplification Tests (NAATs), multi-parameter HIV, hepatitis B, and hepatitis C NAATs.
Based on the distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America is anticipated to hold the largest share of the market during the forecast period.
The key companies involved in the market are Accord Healthcare (Intas Pharmaceuticals Ltd.), Apotex Inc. (SK Capital Partners), Arbutus Biopharma, Arrowhead Pharmaceuticals, Inc., Aurobindo Pharma, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GSK plc, Lupin, Merck & Co., Inc., Par Pharmaceutical (Endo International plc), Teva Pharmaceutical Industries Ltd., and Zydus Healthcare Limited, among others
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.